Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment

MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the 10 Stocks with Huge Catalysts on the Horizon.

The company speeds up the clinical momentum with phase 3 trials, expanded indications, and upcoming data readouts.

Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment

A close-up of a biopharmaceutical research laboratory, with a microscope in the foreground.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is a Switzerland-based clinical-stage biopharmaceutical company specializing in developing next-level medicines for immunologic diseases. The company’s primary and novel asset is Sonelokimab (also known as M1095 or ALX-0761), an investigational Nanobody® that aims to treat inflammatory diseases by independently inhibiting the naturally occurring IL-17 A/A, A/F, and F/F dimers that drive inflammation.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is advancing Sonelokimab, a novel Nanobody® targeting IL-17A/A, A/F, and F/F dimers, into late-stage development for immunologic diseases. The results of the Phase 3 VELA trials launched in May 2025 for hidradenitis suppurativa are expected to arrive in mid-2025. Positive Phase 2 results in psoriatic arthritis support the Phase 3 IZAR program starting in Q4 2024 and are expected to have their primary endpoint readout (week 16) in the first half of 2026.

The company is also pursuing new indications, including palmoplantar pustulosis and axial spondyloarthritis, with multiple trials underway, while having scheduled the Q2 2025 results for August 7.

A modest level of institutional confidence is seen in the stock, with 38 hedge funds holding stakes in the company.

While we acknowledge the risk and potential of MLTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MLTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Long Term Low Risk Stocks to Invest in and 13 Best Low Risk High Growth Stocks to Buy

Disclosure. None.